Measuring and estimating GFR and treatment effect in ADPKD patients: Results and implications of a longitudinal cohort study

PLoS ONE

Volumn 7, Issue 2, 2012, Pages

  Ruggenenti, Piero ^a,b   Gaspari, Flavio ^a   Cannata, Antonio ^a   Carrara, Fabiola ^a   Cella, Claudia ^a   Ferrari, Silvia ^a   Stucchi, Nadia ^a   Prandini, Silvia ^a   Ene Iordache, Bogdan ^a   Diadei, Olimpia ^a   Perico, Norberto ^a   Ondei, Patrizia ^b   Pisani, Antonio ^c   Buongiorno, Erasmo ^d   Messa, Piergiorgio ^e   Dugo, Mauro ^f   Remuzzi, Giuseppe ^a,b  

^a MARIO NEGRI INSTITUTE FOR PHARMACOLOGICAL RESEARCH   (Italy)

^b OSPEDALI RIUNITI   (Italy)

^c FEDERICO II UNIVERSITY HOSPITAL   (Italy)

^d VITO FAZZI HOSPITAL   (Italy)

^e FONDAZIONE IRCCS CA GRANDA OSPEDALE MAGGIORE POLICLINICO   (Italy)

^f OSPEDALE CA FONCELLO   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; IOHEXOL; OCTREOTIDE; RAPAMYCIN;

ADULT; ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; DRUG EFFECT; FEMALE; GLOMERULUS FILTRATION RATE; HUMAN; HYPERTENSION; ITALY; KIDNEY POLYCYSTIC DISEASE; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; PLASMA CLEARANCE; PREDICTION; RELIABILITY; DISEASE COURSE; GENETICS; METABOLISM; METHODOLOGY; MIDDLE AGED; NEPHROLOGY; REPRODUCIBILITY; STATISTICAL MODEL; TREATMENT OUTCOME;

ADULT; COHORT STUDIES; DISEASE PROGRESSION; FEMALE; GLOMERULAR FILTRATION RATE; HUMANS; IOHEXOL; MALE; MIDDLE AGED; MODELS, STATISTICAL; NEPHROLOGY; POLYCYSTIC KIDNEY, AUTOSOMAL DOMINANT; REPRODUCIBILITY OF RESULTS; RESEARCH DESIGN; TREATMENT OUTCOME;

EID: 84857621373     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0032533     Document Type: Article

References (43)

1. Torres VE, Harris PC, Pirson Y, (2007) Autosomal dominant polycystic kidney disease. Lancet 369: 1287-1301.
2. Dalgaard OZ, (1957) Bilateral polycystic disease of the kidneys; a follow-up of two hundred and eighty-four patients and their families. Acta Med Scand Suppl 328: 1-255.
3. Stengel B, Billon S, Van Dijk PC, Jager KJ, Dekker FW, et al. (2003) Trends in the incidence of renal replacement therapy for end-stage renal disease in Europe, 1990-1999. Nephrol Dial Transplant 18: 1824-1833.
4. King BF, Reed JE, Bergstralh EJ, Sheedy PF 2nd, Torres VE, (2000) Quantification and longitudinal trends of kidney, renal cyst, and renal parenchyma volumes in autosomal dominant polycystic kidney disease. J Am Soc Nephrol 11: 1505-1511.
5. Gabow PA, (1993) Autosomal dominant polycystic kidney disease. N Engl J Med 329: 332-342.
6. Perico N, Remuzzi G, (2010) Do mTOR inhibitors still have a future in ADPKD? Nat Rev Nephrol 6: 696-698.
7. Torres VE, Harris PC, (2007) Polycystic kidney disease: Genes, proteins, animal models, disease mechanisms and therapeutic opportunities. J Intern Med 261: 17-31.
8. Tao Y, Kim J, Schrier RW, Edelstein CL, (2005) Rapamycin markedly slows disease progression in a rat model of polycystic kidney disease. J Am Soc Nephrol 16: 46-51.
9. Wu M, Arcaro A, Varga A, Wogetseder A, Le Hir M, et al. (2009) Pulse mTOR inhibitor treatment effectively controls cyst growth but leads to severe parenchymal and glomerular hypertrophy in rat polycystic kidney disease. Am J Physiol Renal Physiol 297: F1597-F1605.
10. Shillingford JM, Murcia NS, Larson CH, Low SH, Hedgepeth R, et al. (2006) The mTOR pathway is regulated by polycystin-1, and its inhibition reverses renal cystogenesis in polycystic kidney disease. Proc Natl Acad Sci U S A 103: 5466-5471.
11. Qian Q, Du H, King BF, Kumar S, Dean PG, et al. (2008) Sirolimus reduces polycystic liver volume in ADPKD patients. J Am Soc Nephrol 19: 631-638.
12. Serra AL, Poster D, Kistler AD, Krauer F, Raina S, et al. (2010) Sirolimus and kidney growth in autosomal dominant polycystic kidney disease. N Engl J Med 363: 820-829.
13. Walz G, Budde K, Mannaa M, Nurnberger J, Wanner C, et al. (2010) Everolimus in patients with autosomal dominant polycystic kidney disease. N Engl J Med 363: 830-840.
14. Levey AS, Stevens LA, Schmid CH, Zhang YL, Castro AF 3rd, et al. (2009) A new equation to estimate glomerular filtration rate. Ann Intern Med 150: 604-612.
15. Rule AD, Larson TS, Bergstralh EJ, Slezak JM, Jacobsen SJ, et al. (2004) Using serum creatinine to estimate glomerular filtration rate: accuracy in good health and in chronic kidney disease. Ann Intern Med 141: 929-937.
16. Poggio ED, Wang X, Greene T, Van Lente F, Hall PM, (2005) Performance of the modification of diet in renal disease and Cockcroft-Gault equations in the estimation of GFR in health and in chronic kidney disease. J Am Soc Nephrol 16: 459-466.
17. Ruggenenti P, Perna A, Remuzzi G, (2005) Preventing Microalbuminuria in Type 2 Diabetes. N Engl J Med 352: 834.
18. Fontsere N, Salinas I, Bonal J, Bayes B, Riba J, et al. (2006) Are prediction equations for glomerular filtration rate useful for the long-term monitoring of type 2 diabetic patients? Nephrol Dial Transplant 21: 2152-2158.
19. Chudleigh RA, Dunseath G, Evans W, Harvey JN, Evans P, et al. (2007) How reliable is estimation of glomerular filtration rate at diagnosis of type 2 diabetes? Diabetes Care 30: 300-305.
20. Heath DA, Knapp MS, Walker WH, (1968) Comparison between inulin and 51Cr-labelled edetic acid for the measurement of glomerular filtration-rate. Lancet 2: 1110-1112.
21. Gaspari F, Perico N, Ruggenenti P, Mosconi L, Amuchastegui CS, et al. (1995) Plasma clearance of nonradioactive iohexol as a measure of glomerular filtration rate. J Am Soc Nephrol 6: 257-263.
22. Price M, (1972) Comparison of creatinine clearance to inulin clearance in the determination of glomerular filtration rate. J Urol 107: 339-340.
23. Brochner-Mortensen J, Giese J, Rossing N, (1969) Renal inulin clearance versus total plasma clearance of 51Cr-EDTA. Scand J Clin Lab Invest 23: 301-305.
24. Rehling M, Moller ML, Thamdrup B, Lund JO, Trap-Jensen J, (1984) Simultaneous measurement of renal clearance and plasma clearance of 99mTc-labelled diethylenetriaminepenta-acetate, 51Cr-labelled ethylenediaminetetra-acetate and inulin in man. Clin Sci (Lond) 66: 613-619.
25. Brandstrom E, Grzegorczyk A, Jacobsson L, Friberg P, Lindahl A, et al. (1998) GFR measurement with iohexol and 51Cr-EDTA. A comparison of the two favoured GFR markers in Europe. Nephrol Dial Transplant 13: 1176-1182.
26. Effersoe H, Rosenkilde P, Groth S, Jensen LI, Golman K, (1990) Measurement of renal function with iohexol. A comparison of iohexol, 99mTc-DTPA, and 51Cr-EDTA clearance. Invest Radiol 25: 778-782.
27. Brown SC, O'Reilly PH, (1991) Iohexol clearance for the determination of glomerular filtration rate in clinical practice: evidence for a new gold standard. J Urol 146: 675-679.
28. Erley CM, Bader BD, Berger ED, Vochazer A, Jorzik JJ, et al. (2001) Plasma clearance of iodine contrast media as a measure of glomerular filtration rate in critically ill patients. Crit Care Med 29: 1544-1550.
29. Berg UB, Back R, Celsi G, Halling SE, Homberg I, et al. (2011) Comparison of plasma clearance of iohexol and urinary clearance of inulin for measurement of GFR in children. Am J Kidney Dis 57: 55-61.
30. Ruggenenti P, Remuzzi A, Ondei P, Fasolini G, Antiga L, et al. (2005) Safety and efficacy of long-acting somatostatin treatment in autosomal-dominant polycystic kidney disease. Kidney Int 68: 206-216.
31. Perico N, Antiga L, Caroli A, Ruggenenti P, Fasolini G, et al. (2010) Sirolimus therapy to halt the progression of ADPKD. J Am Soc Nephrol 21: 1031-1040.
32. Brochner-Mortensen J, (1972) A simple method for the determination of glomerular filtration rate. Scand J Clin Lab Invest 30: 271-274.
33. Gaspari F, Perico N, Matalone M, Signorini O, Azzollini N, et al. (1998) Precision of plasma clearance of iohexol for estimation of GFR in patients with renal disease. J Am Soc Nephrol 9: 310-313.
34. Lin LI, (1989) A concordance correlation coefficient to evaluate reproducibility. Biometrics 45: 255-268.
35. Gaspari F, Ferrari S, Stucchi N, Centemeri E, Carrara F, et al. (2004) Performance of different prediction equations for estimating renal function in kidney transplantation. Am J Transplant 4: 1826-1835.
36. Rule AD, Torres VE, Chapman AB, Grantham JJ, Guay-Woodford LM, et al. (2006) Comparison of methods for determining renal function decline in early autosomal dominant polycystic kidney disease: the consortium of radiologic imaging studies of polycystic kidney disease cohort. J Am Soc Nephrol 17: 854-862.
37. Orskov B, Borresen ML, Feldt-Rasmussen B, Ostergaard O, Laursen I, et al. (2010) Estimating glomerular filtration rate using the new CKD-EPI equation and other equations in patients with autosomal dominant polycystic kidney disease. Am J Nephrol 31: 53-57.
38. (1997) Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy. The GISEN Group (Gruppo Italiano di Studi Epidemiologici in Nefrologia). Lancet 349: 1857-1863.
39. Barnett AH, Bain SC, Bouter P, Karlberg B, Madsbad S, et al. (2004) Angiotensin-receptor blockade versus converting-enzyme inhibition in type 2 diabetes and nephropathy. N Engl J Med 351: 1952-1961.
40. Kuypers DR, Neumayer HH, Fritsche L, Budde K, Rodicio JL, et al. (2004) Calcium channel blockade and preservation of renal graft function in cyclosporine-treated recipients: a prospective randomized placebo-controlled 2-year study. Transplantation 78: 1204-1211.
41. Schwartz GJ, Furth S, Cole SR, Warady B, Munoz A, (2006) Glomerular filtration rate via plasma iohexol disappearance: pilot study for chronic kidney disease in children. Kidney Int 69: 2070-2077.
42. Schutzer KM, Svensson MK, Zetterstrand S, Eriksson UG, Wahlander K, (2010) Reversible elevations of serum creatinine levels but no effect on glomerular filtration during treatment with the direct thrombin inhibitor AZD0837. Eur J Clin Pharmacol 66: 903-910.
43. Grantham JJ, Chapman AB, Torres VE, (2006) Volume progression in Autosomal Dominant Polycystic Kidney Disease: The major factor determining clinical outcomes. Clin J Am Soc Nephrol 1: 148-157.